InsidersTradesSigma
Total declarations
Companies
▲ Purchases (11 ops.)
▼ Sales (0 ops.)
Discover the detailed record of transactions filed by PATIENCE JOHN, Director. Director active across 2 companies, notably BIODESIX INC. Aggregated, 13 filings have been published. Total volume traded: €1.9m. The latest transaction was disclosed on 7 April 2022 — Acquisition. Regulator: SEC (Form 4). All data is free.
Declarations13 total
€460,199279,329 shares@ €1.64750.85% mcap24.6% of flow
Common Stock
SEC:0001567619-22-008354:0·
Ideal exit: 2 Jan 2023 (T+270)
€528,162137,931 shares@ €3.82920.98% mcap75.0% of flow
Common Stock
SEC:0001567619-22-000275·
Ideal exit: 26 Sept 2022 (T+270)
€528,162137,931 shares@ €3.82920.98% mcap28.3% of flow
Common Stock
SEC:0001567619-22-000275:0·
Ideal exit: 26 Sept 2022 (T+270)
€143,99921,702 shares@ €6.6353100.0% of flow
Common Stock
SEC:0001628280-21-024838·
€143,99921,702 shares@ €6.635350.0% of flow
Common Stock
SEC:0001628280-21-024838:0·
€54,93010,000 shares@ €5.4930.10% mcap7.8% of flow
Common Stock
SEC:0001567619-21-021148·
Ideal exit: 20 Aug 2022 (T+270)
€54,93010,000 shares@ €5.4930.10% mcap2.9% of flow
Common Stock
SEC:0001567619-21-021148:0·
Ideal exit: 20 Aug 2022 (T+270)
€53,1929,497 shares@ €5.60090.098% mcap7.6% of flow
Common Stock
SEC:0001567619-21-020954·
Ideal exit: 15 Aug 2022 (T+270)
€53,1929,497 shares@ €5.60090.098% mcap2.8% of flow
Common Stock
SEC:0001567619-21-020954:0·
Ideal exit: 15 Aug 2022 (T+270)
€57,7998,396 shares@ €6.88410.11% mcap8.2% of flow
Common Stock
SEC:0001567619-21-016211·
Ideal exit: 16 May 2022 (T+270)
€57,7998,396 shares@ €6.88410.11% mcap3.1% of flow
Common Stock
SEC:0001567619-21-016211:0·
Ideal exit: 16 May 2022 (T+270)
€9,7491,604 shares@ €6.07820.018% mcap1.4% of flow
Common Stock
SEC:0000905148-21-000612·
Ideal exit: 14 May 2022 (T+270)
€9,7491,604 shares@ €6.07820.018% mcap0.5% of flow
Common Stock
SEC:0000905148-21-000612:0·
Ideal exit: 14 May 2022 (T+270)
13 of 13 declarations
About PATIENCE JOHN
PATIENCE JOHN is a Director at BIODESIX INC and Accelerate Diagnostics, Inc. In this role, he contributes to overseeing the activities of these companies and making strategic decisions. His expertise is valuable for guiding these organizations in their development initiatives.
